Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Research & Development (2017 - 2025)

Autolus Therapeutics' Research & Development history spans 6 years, with the latest figure at $35.6 million for Q4 2025.

  • For Q4 2025, Research & Development rose 15.58% year-over-year to $35.6 million; the TTM value through Dec 2025 reached $117.7 million, down 14.99%, while the annual FY2025 figure was $117.7 million, 14.99% down from the prior year.
  • Research & Development reached $35.6 million in Q4 2025 per AUTL's latest filing, up from $27.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $40.3 million in Q3 2024 to a low of $7.5 million in Q4 2022.
  • Average Research & Development over 4 years is $30.3 million, with a median of $30.8 million recorded in 2022.
  • Peak YoY movement for Research & Development: surged 397.39% in 2023, then plummeted 30.83% in 2025.
  • A 4-year view of Research & Development shows it stood at $7.5 million in 2022, then soared by 397.39% to $37.5 million in 2023, then decreased by 17.88% to $30.8 million in 2024, then rose by 15.58% to $35.6 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Research & Development are $35.6 million (Q4 2025), $27.9 million (Q3 2025), and $27.4 million (Q2 2025).